journal article·2026-03-24

Lung-Accumulating Mucin 5AC Silencing by Noninflammatory Lipid Nanoparticles for Asthma Treatment

Zhiqiang Zhao, Xinzhu Shan, Weixue Wang, Changdi Cao, Dian Chen, Lanhe Chu, Yan Zeng, Yunxuan Liu, Yue Yang, Yun Wu, Yanping Zhao, Junhe Chen, Zhenfan Wang, Xiaojuan Liu, Yahong Chen, Xueguang Lu, Jian Zhou, Lei Miao, Cong Luo

ACS Nano· Volume 20· Issue 11
Publisher page

Abstract

Overexpression of Mucin 5AC (MUC5AC) drives excessive mucus secretion and respiratory obstruction, contributing to mortality in severe asthma and mucous obstructive lung diseases (MOLDs). While siRNA-mediated silencing of MUC5AC expression represents an effective strategy to treat MOLDs, our investigation reveals that intratracheal administration of FDA-approved lipid nanoparticle (LNP) carriers can paradoxically lead to MUC5AC increases due to inflammatory side effects. To address this challenge, we designed noninflammatory LNPs for asthma treatment by (I) developing ionizable cationic lipids with low immunogenicity, (II) incorporating anti-inflammatory natural compound derivatives into LNPs, and(III) reducing the N/P ratio of LNP formulations. After three rounds of screening–evaluating gene silencing efficiency (in vitro and in vivo), LNP physicochemical properties and biosafety─we identify a lead candidate formulation (Formulation 1) that achieves 85% MUC5AC silencing efficiency in vivo, outperforming the integrin αvβ6 ligand-modified siRNA (69%), and demonstrates notably improved biosafety when compared to SM102 LNPs and MC3 LNPs. In house dust mite (HDM)-induced asthmatic mice, siMuc5ac -LNPs effectively alleviate airway inflammation and obstruction with a sustained preventive effect. Moreover, Formulation 1 effectively suppresses MUC5AC secretion in a Chronic Obstructive Pulmonary Disease (COPD) patient-derived organoid model. Collectively, we develop a clinically translatable, noninflammatory siRNA delivery platform with therapeutic potential for asthma and other MOLDs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Advancements in Transdermal Drug Delivery · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, Wuya College of Innovation

Shenyang Pharmaceutical University

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences

Peking University

Beijing Key Laboratory of Molecular Pharmaceutics, School of Pharmaceutical Sciences

Department of Respiratory and Critical Care Medicine

Peking University Third Hospital

Beijing Tide Pharmaceutical Co., Ltd.

University of North Carolina

Department of Thoracic Surgery Peking University People’s Hospital, 11 Xizhimen South Street, Beijing 100044, China

Thoracic Oncology Institute Peking University People’s Hospital Beijing

Clinical Stem Cell Research Center

Research Center for Chronic Airway Diseases

Peking University Health Science Center

Key Laboratory of Colloid, Interface and Chemical Thermodynamics

Institute of Chemistry, Chinese Academy of Sciences

Peking University-Yunnan Baiyao International Medical Research Center

Funding

National Key Research and Development Program of China · Liaoning Revitalization Talents Program · Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park · Natural Science Foundation of Beijing Municipality · National Natural Science Foundation of China · Project of China-Japan Joint International Laboratory of Advanced Drug Delivery System Research and Translation of Liaoning Province

References (75)

Show source-provided references
1. 10.1136/bmj.m23410.1136/bmj.m234 ↗
2. 10.1164/rccm.201011-1796PP10.1164/rccm.201011-1796PP ↗
3. 10.1146/annurev.med.58.071905.10531610.1146/annurev.med.58.071905.105316 ↗
4. 10.1038/nri373910.1038/nri3739 ↗
5. 10.1016/j.jaip.2025.01.01010.1016/j.jaip.2025.01.010 ↗
6. 10.1164/rccm.200212-1437OC10.1164/rccm.200212-1437OC ↗
7. 10.1016/j.xcrm.2023.10137110.1016/j.xcrm.2023.101371 ↗
8. 10.3390/antiox1210186710.3390/antiox12101867 ↗
9. 10.1016/j.addr.2017.12.00610.1016/j.addr.2017.12.006 ↗
10. 10.1164/rccm.201802-0245OC10.1164/rccm.201802-0245OC ↗
11. 10.1016/j.chest.2017.11.00810.1016/j.chest.2017.11.008 ↗
12. 10.1038/nature1280710.1038/nature12807 ↗
13. 10.1164/rccm.201603-0526LE10.1164/rccm.201603-0526LE ↗
14. 10.1038/ncomms728110.1038/ncomms7281 ↗
15. 10.1164/rccm.200607-1011OC10.1164/rccm.200607-1011OC ↗
16. 10.1038/nrg200610.1038/nrg2006 ↗
17. 10.1016/j.apsb.2013.06.00510.1016/j.apsb.2013.06.005 ↗
18. 10.1038/nature0287010.1038/nature02870 ↗
19. 10.1016/j.addr.2009.04.00110.1016/j.addr.2009.04.001 ↗
20. 10.1038/nrd274210.1038/nrd2742 ↗
21. 10.1021/acs.chemrev.7b0019410.1021/acs.chemrev.7b00194 ↗
22. 10.1016/j.addr.2023.11511110.1016/j.addr.2023.115111 ↗
23. 10.1016/j.pmatsci.2023.10107010.1016/j.pmatsci.2023.101070 ↗
24. 10.1016/j.apsb.2025.07.00410.1016/j.apsb.2025.07.004 ↗
25. 10.1016/j.critrevonc.2015.10.01510.1016/j.critrevonc.2015.10.015 ↗
26. 10.1016/j.biomaterials.2013.04.06010.1016/j.biomaterials.2013.04.060 ↗
27. 10.3390/nano704007710.3390/nano7040077 ↗
28. 10.1016/j.apsb.2025.04.00310.1016/j.apsb.2025.04.003 ↗
29. 10.1002/EXP.2021000810.1002/EXP.20210008 ↗
30. 10.1002/EXP.2023017810.1002/EXP.20230178 ↗
31. 10.1016/j.addr.2023.11499010.1016/j.addr.2023.114990 ↗
32. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
33. 10.1038/d41573-020-00078-010.1038/d41573-020-00078-0 ↗
34. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
35. 10.1038/nrd.2017.24310.1038/nrd.2017.243 ↗
36. 10.1056/NEJMoa171615310.1056/NEJMoa1716153 ↗
37. 10.1093/ehjci/ehaa946.212910.1093/ehjci/ehaa946.2129 ↗
38. 10.1038/s41467-021-26777-910.1038/s41467-021-26777-9 ↗
39. 10.1016/j.semcancer.2021.01.00310.1016/j.semcancer.2021.01.003 ↗
40. 10.1186/s40169-015-0068-z10.1186/s40169-015-0068-z ↗
41. 10.1038/s41565-022-01071-x10.1038/s41565-022-01071-x ↗
42. 10.1038/s41565-023-01404-410.1038/s41565-023-01404-4 ↗
43. 10.1016/j.addr.2023.11517510.1016/j.addr.2023.115175 ↗
44. 10.1038/s41551-023-01131-010.1038/s41551-023-01131-0 ↗
45. 10.1016/j.immuni.2022.10.01410.1016/j.immuni.2022.10.014 ↗
46. 10.1016/j.phymed.2021.15369610.1016/j.phymed.2021.153696 ↗
47. 10.1002/med.2148410.1002/med.21484 ↗
48. 10.1039/D2NP00063F10.1039/D2NP00063F ↗
49. 10.1186/s12931-024-02774-610.1186/s12931-024-02774-6 ↗
50. 10.1021/acsnano.3c0166810.1021/acsnano.3c01668 ↗
51. 10.1016/j.imlet.2017.10.00610.1016/j.imlet.2017.10.006 ↗
52. 10.7717/peerj.1469510.7717/peerj.14695 ↗
53. 10.1016/j.cyto.2015.08.26210.1016/j.cyto.2015.08.262 ↗
54. 10.4049/jimmunol.090061410.4049/jimmunol.0900614 ↗
55. 10.1016/j.isci.2021.10347910.1016/j.isci.2021.103479 ↗
56. 10.1096/fj.202101977RR10.1096/fj.202101977RR ↗
57. 10.1016/j.alit.2024.05.00510.1016/j.alit.2024.05.005 ↗
58. 10.1080/1744666X.2016.120046710.1080/1744666X.2016.1200467 ↗
59. 10.1038/s41590-022-01160-y10.1038/s41590-022-01160-y ↗
60. 10.1021/jacs.3c1401010.1021/jacs.3c14010 ↗
61. 10.1073/pnas.231127612010.1073/pnas.2311276120 ↗
62. 10.1021/jacs.5c0789710.1021/jacs.5c07897 ↗
63. 10.1038/s41467-025-61688-z10.1038/s41467-025-61688-z ↗
64. 10.1016/j.phymed.2021.15369610.1016/j.phymed.2021.153696 ↗
65. 10.3892/ol.2020.1234510.3892/ol.2020.12345 ↗
66. 10.1016/j.biocel.2018.04.01310.1016/j.biocel.2018.04.013 ↗
67. 10.1016/j.jconrel.2022.11.02210.1016/j.jconrel.2022.11.022 ↗
68. 10.1038/s41565-023-01548-310.1038/s41565-023-01548-3 ↗
69. 10.1002/advs.20240540610.1002/advs.202405406 ↗
70. 10.1016/j.jconrel.2022.10.02010.1016/j.jconrel.2022.10.020 ↗
71. 10.1038/s41565-025-01974-510.1038/s41565-025-01974-5 ↗
72. 10.1016/j.phymed.2024.15629910.1016/j.phymed.2024.156299 ↗
73. 10.1007/978-1-59745-447-610.1007/978-1-59745-447-6 ↗
74. 10.1038/s41421-022-00422-110.1038/s41421-022-00422-1 ↗
75. 10.1073/pnas.180630811510.1073/pnas.1806308115 ↗